Amphastar Pharmaceuticals reported strong financial results for the fourth quarter of 2024, with net revenues increasing to $186.5 million and GAAP net income reaching $38.0 million. The company also exceeded its long-term goal for Primatene MIST® annual sales and saw significant growth in BAQSIMI® factory sales.
Net revenues for Q4 2024 increased to $186.5 million, up from $178.1 million in Q4 2023.
GAAP net income for Q4 2024 was $38.0 million, or $0.74 per diluted share.
Adjusted non-GAAP net income for Q4 2024 was $47.2 million, or $0.92 per diluted share.
Primatene MIST® sales increased by 18% in Q4 2024, and BAQSIMI® sales contributed significantly to product revenues.
Amphastar Pharmaceuticals anticipates continued growth in its proprietary pipeline and brands like Primatene MIST® and BAQSIMI® in 2025.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance